Benzinga | Mar 10, 2021 06:37AM EST

Luminex Submits Joint SARS-CoV-2 And Flu/RSV Respiratory Panel To FDA For Emergency Use Authorization

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target. The ARIES(r) Flu A/B & RSV+SARS-CoV-2 Assay can be run on all Luminex ARIES(r) Systems. This submission represents completion of a key milestone in a Luminex funding award from the Biomedical Advanced Research and Development Authority (BARDA), which helped support the rapid development and validation of the assay.